Introduction {#Sec1}
============

Osteoporosis and its associated fragility fractures are debilitating conditions that result in significant morbidity and mortality worldwide \[[@CR1]\]. Fragility fractures are associated with decline in physical and cognitive function, high rates of disability, loss of independence \[[@CR2]\], and increased mortality---up to one in four patients in Asia who sustain a hip fracture die within a year, and less than half of those who survive regain their previous level of function \[[@CR3], [@CR4]\]. Importantly, patients who sustain a fracture are at imminent risk of a future fracture, defined as risk of near-term fracture within the next 12--24 months \[[@CR5]--[@CR7]\]. In Asia, 6--8% of hip fracture patients suffer another fracture within 2 years, with second fractures occurring as early as 4 weeks after the first event \[[@CR8]--[@CR10]\].

As a result of the exponentially aging population in Asia, it is projected that by 2050, more than half of the world's fractures and an estimated 2.6 million hip fractures will occur in the region \[[@CR11], [@CR12]\]. Despite this, osteoporosis remains alarmingly underdiagnosed and undertreated in Asia, even among patients who have already sustained a fragility fracture. In a study of over 1000 postmenopausal women with hip fractures from seven countries in Asia, only one in three underwent bone mineral density (BMD) testing and received osteoporosis medications after discharge \[[@CR13]\].

Oral bisphosphonates, particularly alendronate, are the most commonly prescribed anti-osteoporosis medication in the region \[[@CR14]--[@CR16]\]; however, two out of three patients in Asia are non-adherent to oral bisphosphonates within 3--12 months of prescription \[[@CR17]--[@CR19]\]. As a result of the high burden and proportion of patients with imminent risk of fracture in the region, there is a strong need for more potent medications that can impact outcomes early in the course of the disease \[[@CR20], [@CR21]\].

Romosozumab is a bone-forming agent and monoclonal antibody that binds and inhibits sclerostin, with a dual effect of increasing bone formation and decreasing bone resorption \[[@CR22], [@CR23]\]. Its unique dual mechanism of action offers more potent and rapid improvement in bone mass, structure, and strength to reduce the risk of fractures, differentiating it from other anti-osteoporosis medications such as antiresorptives and parathyroid hormone analogues that decrease and increase, respectively, both bone formation and resorption \[[@CR24]\]. In the phase III FRActure study in postmenopausal woMen with ostEoporosis (FRAME; NCT01575834), romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after transition to denosumab, at 24 months \[[@CR25]\]. On the basis of this trial, romosozumab was approved in Japan in January 2019 for the treatment of osteoporosis in patients at high risk of fracture \[[@CR26]\].

The phase III Active-contRolled fraCture study in postmenopausal women with osteoporosis at High risk (ARCH) was the first registrational head-to-head study to demonstrate superior antifracture efficacy of a novel osteoporosis medication, romosozumab, over alendronate, the current standard of care \[[@CR27]\]. Compared with alendronate treatment alone for 24 months, romosozumab treatment in the first year followed by alendronate in the second year significantly reduced the risk of new vertebral, clinical, non-vertebral, and hip fractures in postmenopausal women at high fracture risk \[[@CR27]\]. In ARCH, approximately 7% of global enrollment was from the Asia Pacific region. In this post hoc analysis of the ARCH trial, we evaluated the efficacy and safety of romosozumab followed by alendronate compared with alendronate alone in patients from East Asia.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

ARCH was a phase III, multicenter, international, randomized, double-blind trial. Full details of the study design and eligibility criteria have been previously reported \[[@CR27]\]. Briefly, ambulatory postmenopausal women aged 55--90 years with severe osteoporosis, from 41 countries globally, were randomly assigned (1:1) to monthly subcutaneous romosozumab 210 mg (Amgen, Inc., Thousand Oaks, CA, USA, and UCB Pharma, Brussels, Belgium) or weekly oral alendronate 70 mg (Merck & Co., Inc., Kenilworth, NJ, USA) for 12 months, followed by open-label alendronate in both groups. Patients also received daily calcium and vitamin D supplements. Patients had a BMD T-score of − 2.5 or lower at the total hip or femoral neck and either one or more moderate or severe vertebral fractures or two or more mild vertebral fractures, or a BMD T-score of − 2.0 or lower at the total hip or femoral neck and either two or more moderate or severe vertebral fractures or a fracture of the proximal femur sustained 3--24 months before randomization. Use of drugs affecting bone metabolism within defined washout periods was an exclusion criterion in the protocol. Patients enrolled in ARCH from Hong Kong, Republic of Korea, and Taiwan were included in this East Asian post hoc analysis.

The study was conducted in accordance with the Declaration of Helsinki, the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation, and local laws and was approved by an independent ethics committee, research ethics board, or institutional review board for each study site ([ClinicalTrials.gov](http://clinicaltrials.gov) NCT01631214). All patients provided written informed consent. Amgen provided financial support for the study.

Assessment and procedures {#Sec4}
-------------------------

Assessments and procedures for patients enrolled in the study have been previously described in detail \[[@CR27]\]. Briefly, lateral radiographs of the thoracic and lumbar spine were obtained at screening and months 12 and 24. Radiographs were assessed at a central imaging center, as were non-vertebral fractures. BMD at the lumbar spine and proximal femur were evaluated by dual-energy X-ray absorptiometry (DXA) at baseline and every 12 months thereafter.

Adverse events (AEs) were reported by individual trial sites and summarized according to the Medical Dictionary for Regulatory Activities (MedDRA) version 19.1 coding system and the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0 grading system. Serious cardiovascular AEs were adjudicated by the Duke Clinical Research Institute, and potential cases of osteonecrosis of the jaw and atypical femoral fracture were adjudicated by independent committees. Serum was tested for anti-romosozumab antibodies at day 1 and until month 24; samples that were positive for binding antibodies were assessed for neutralizing antibodies.

Study endpoint {#Sec5}
--------------

The primary endpoints of the main study were the incidence of new vertebral fractures at 24 months and incidence of clinical fractures (non-vertebral and symptomatic vertebral fracture) at the time of the primary analysis (i.e., when clinical fracture events had been confirmed in at least 330 patients and all patients had the opportunity to complete the month 24 visit). Secondary endpoints included BMD at the lumbar spine, total hip, and femoral neck at 12 and 24 months, incidences of non-vertebral and hip fracture at the time of the primary analysis, and safety outputs, including adjudicated serious cardiovascular AEs, osteonecrosis of the jaw events, and atypical femoral fracture events.

Statistical analysis {#Sec6}
--------------------

This East Asia post hoc subanalysis of patients enrolled in Hong Kong, Republic of Korea, and Taiwan evaluated the same endpoints as the main ARCH study. The East Asia cohort analysis was not powered to determine statistical significance between groups for antifracture efficacy.

Analyses of vertebral fracture endpoints included all randomly assigned patients with a baseline radiograph and ≥ 1 radiograph obtained post-baseline. Any missing post-baseline radiograph assessment was imputed using the status from the last non-missing post-baseline visit. Analyses of other fracture endpoints included all randomized patients. For the incidence of new vertebral and new or worsening vertebral fractures, risk ratios were determined based on the Mantel--Haenszel method, with treatment comparison assessed using a logistic-regression model stratified by age (\< 75 vs ≥ 75 years), presence or absence of severe vertebral fracture at baseline, and baseline BMD T-score at the total hip (≤ − 2.5 vs \> − 2.5). For other fracture endpoints, treatment groups were compared based on a Cox proportional-hazards model adjusted for age (\< 75 vs ≥ 75 years), presence or absence of severe vertebral fracture at baseline, and baseline BMD T-score at the total hip.

Percentage changes from baseline in BMD were assessed in patients who had a baseline and at least one post-baseline measurement. Between-group comparisons of BMD changes were analyzed using an analysis-of-covariance model with adjustment for age, severe vertebral fracture at baseline, baseline BMD, machine type, and baseline BMD-by-machine-type interaction, with missing values imputed by carrying forward the last post-baseline observation.

The safety analysis included all randomly assigned patients who received at least one dose of romosozumab or alendronate in the double-blind period. Incidence rates of AEs at the time of the primary analysis were cumulative and included events in the double-blind and in the open-label periods in patients who received at least one dose of open-label alendronate.

Results {#Sec7}
=======

Patients {#Sec8}
--------

Of 4093 patients randomized in the ARCH study, 275 were from Hong Kong, Republic of Korea, and Taiwan and were included in this East Asia subanalysis. The demographic and clinical characteristics of East Asian patients at baseline were balanced between the two treatment groups (Table [1](#Tab1){ref-type="table"}) and were largely similar to those of the global ARCH population in terms of age and history of prior fracture, although the median Fracture Risk Assessment Tool (FRAX^®^) score was higher in this subgroup (25.7) compared with the global population (17.9). The mean age of East Asian patients was 74.6 years, and more than half (52.7%) were ≥ 75 years old at enrollment. The mean body mass index (BMI) of East Asian patients was slightly lower than for the global population (23.0 vs 25.0 kg/m^2^). All patients had a previous osteoporotic fracture at age ≥ 45 years, and 98% had a prevalent vertebral fracture. Mean BMD T-scores were − 3.0 at the lumbar spine, − 2.8 at the total hip, and − 3.1 at the femoral neck. Among East Asian patients randomized in the ARCH study, 10.5% had previously received osteoporosis medications outside of the respective defined washout periods.Table 1Demographics and baseline characteristics of East Asian patients in the ARCH studyCharacteristicAlendronate (*n* = 146)Romosozumab (*n* = 129)Mean ± SD age, years74.0 ± 6.775.2 ± 7.0Age ≥ 75 years, *n* (%)71.0 (48.6)74.0 (57.4)Mean ± SD BMI, kg/m^2^23.5 ± 3.123.2 ± 3.1Mean ± SD BMD T-score  Lumbar spine− 3.0 ± 1.1− 3.1 ± 1.2  Total hip− 2.8 ± 0.7− 2.9 ± 0.7  Femoral neck− 3.1 ± 0.5− 3.1 ± 0.5Previous osteoporosis fracture at ≥ 45 years of age, *n* (%)146 (100)129 (100)Prevalent vertebral fracture, *n* (%)143 (97.9)127 (98.4)Grade of most severe vertebral fracture^a^  Mild6 (4.1)3 (2.3)  Moderate36 (24.7)43 (33.3)  Severe101 (69.2)81 (62.8)Previous non-vertebral fracture at ≥ 45 years of age, *n* (%)^b^42 (28.8)40 (31.0)Previous hip fracture, *n* (%)^b^15 (10.3)11 (8.5)Median FRAX score (range)^c^25.6 (22.0--32.4)25.7 (22.2--31.4)Prior osteoporosis medication use, *n* (%)  Oral bisphosphonate  Intravenous bisphosphonate  SERM  PTH or PTH derivatives  Other12 (8.2)8 (5.5)0 (0.0)1 (0.7)4 (2.7)2 (1.4)17 (13.2)15 (11.6)1 (0.8)1 (0.8)1 (0.8)2 (1.6)^a^Assessed with the use of the Genant grading scale; ^b^excludes pathologic or high-trauma fracture; ^c^the country-specific FRAX \[[@CR28]\] score, developed by the World Health Organization ([www.shef.ac.uk/frax/](http://www.shef.ac.uk/frax/)), indicates the 10-year probability of major osteoporotic fracture, expressed as a percentage and calculated with BMD. *PTH*, parathyroid hormone; *SD*, standard deviation; *SERM*, selective estrogen receptor modulator

Efficacy {#Sec9}
--------

### Fracture {#Sec10}

Among East Asian patients, treatment with romosozumab followed by alendronate reduced the risk of new vertebral fractures at 24 months by 60% compared with alendronate alone (2.5% vs 6.6%; *P* = 0.11; Fig. [1](#Fig1){ref-type="fig"}). Data from the primary analysis showed that treatment with romosozumab followed by alendronate resulted in a 44% lower risk of clinical fracture than with alendronate alone (7.0% vs 11.6%; *P* = 0.15; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Incidence of **a** new vertebral fractures through 24 months (LOCF imputation) and **b** clinical fracture at the time of the primary analysis\* in the ARCH East Asian and Global populations. n/N presented in bars = number of patients with ≥ 1 fracture/all randomly assigned patients (for clinical fracture) or all randomly assigned patients with a baseline radiograph and ≥ 1 radiograph obtained post-baseline (for new vertebral fractures). \*Median follow-up at the time of primary analysis was 33 months (interquartile range 27--40). RRR relative risk reduction

Reductions in risk of new vertebral fractures at 24 months among East Asian patients were generally similar to the last-observation-carried-forward (LOCF) analysis of the global population (60% vs 50%; Fig. [1](#Fig1){ref-type="fig"}), although this finding did not reach statistical significance among East Asian patients as this analysis was not powered to demonstrate differences between subgroups.

At the time of the primary analysis, romosozumab followed by alendronate also resulted in a 60% lower risk of non-vertebral fracture than alendronate alone (95% confidence interval \[CI\] 0.15--1.03; *P* = 0.05), with fractures occurring in 4.7% (6/129) of patients in the romosozumab-to-alendronate group vs 10.3% (15/146) of those in the alendronate-only group. Four patients (2.7%) in the alendronate-only group had suffered a hip fracture by the time of the primary analysis, while none of the patients treated with romosozumab followed by alendronate did.

### Bone mineral density {#Sec11}

In both the global and East Asian populations, patients who received romosozumab had significantly greater percentage gains in BMD from baseline at all measured sites at both 12 and 24 months than patients who received alendronate alone (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Changes in BMD from baseline at months 12 and 24 among the ARCH East Asian and global populations in the **a** lumbar spine, **b** total hip, and **c** femoral neck. \**P* \< 0.001 vs alendronate; ^†^*P* = 0.002 vs alendronate. LSM least-squares mean, SE standard error

Among East Asian patients, romosozumab treatment achieved greater gains in mean BMD at the lumbar spine (8.2%; 95% CI 6.7--9.7, *P* \< 0.001), total hip (2.4%; 95% CI 1.4--3.3, *P* \< 0.001), and femoral neck (1.7%; 95% CI 0.6--2.8, *P* = 0.002) at month 12 compared with alendronate. After transitioning to alendronate, the significantly greater BMD increases gained with romosozumab compared with alendronate in the first year were maintained at 24 months at key skeletal sites. Initiating osteoporosis treatment with a year of romosozumab before alendronate achieved significantly greater percentage gains in mean BMD at 24 months from baseline by a further 9.0% (95% CI 7.2--10.7, *P* \< 0.001) at the lumbar spine, 3.3% (95% CI 2.3--4.4, *P* \< 0.001) at the total hip, and 3.0% (95% CI 1.9--4.1, *P* \< 0.001) at the femoral neck than with alendronate alone.

Safety {#Sec12}
------

The majority of East Asian patients received all 12 doses of romosozumab, with a mean cumulative romosozumab exposure of 2289 mg (range 210--2520 mg). Nine patients in each treatment group had an AE leading to study treatment discontinuation during the primary analysis period. Common AEs were largely similar between both treatment groups in the East Asian population, except back pain, musculoskeletal pain, pain in extremity, and falls, which occurred in more patients in the alendronate group, and upper respiratory tract infection and cough, which occurred in more patients in the romosozumab group (Table [2](#Tab2){ref-type="table"}). In the East Asian population, hypersensitivity was reported in 19 (13.0%) patients receiving alendronate and 22 (17.1%) patients receiving romosozumab during the double-blind period, while in the global population it was reported in 118 (5.9%) and 122 (6.0%) patients in the alendronate and romosozumab groups, respectively. Among East Asian patients, injection-site reactions were reported in 17 (11.6%) of those receiving alendronate and 21 (16.3%) of those receiving romosozumab, while in the global population it was reported in 53 (2.6%) and 90 (4.4%) patients in the alendronate and romosozumab groups, respectively. It is important to note that the East Asian population in this study is substantially smaller than the overall global population. In the East Asian population, between-group differences for hypersensitivity events and injection-site reactions are 3 and 4 patients, respectively. The types of events for both hypersensitivity and injection-site reactions that were reported by the East Asian population were similar to that of the global population.Table 2Adverse events in East Asian patients in the ARCH studyEvent, *n* (%)Month 12: double-blind periodPrimary analysis: double-blind and open-label period^a^Alendronate (*n* = 146)Romosozumab (*n* = 129)Alendronate to alendronate (*n* = 146)Romosozumab to alendronate (*n* = 129)Adverse event during treatment^b^  Upper respiratory tract infection  Back pain  Musculoskeletal pain  Arthralgia  Fall  Pain in extremity  Cough126 (86.3)64 (43.8)31 (21.2)21 (14.4)19 (13.0)19 (13.0)15 (10.3)9 (6.2)115 (89.1)65 (50.4)14 (10.9)4 (3.1)21 (16.3)11 (8.5)7 (5.4)14 (10.9)135 (92.5)96 (65.8)52 (35.6)41 (28.1)47 (32.2)51 (34.9)36 (24.7)25 (17.1)121 (93.8)84 (65.1)41 (31.8)17 (13.2)43 (33.3)36 (27.9)28 (21.7)31 (24.0)Serious adverse event18 (12.3)14 (10.9)51 (34.9)41 (31.8)Adjudicated serious cardiovascular event^c^2 (1.4)2 (1.6)6 (4.1)5 (3.9)  Cardiac ischemic event  Cerebrovascular event  Heart failure1 (0.7)01 (0.7)1 (0.8)1 (0.8)02 (1.4)2 (1.4)2 (1.4)3 (2.3)1 (0.8)0Death0001 (0.8)Event leading to discontinuation of trial regimen2 (1.4)4 (3.1)9 (6.2)9 (7.0)Event leading to discontinuation of trial participation01 (0.8)3 (2.1)5 (3.9)Event of interest^d^  Hypersensitivity19 (13.0)22 (17.1)29 (19.9)29 (22.5)  Injection-site reaction17 (11.6)21 (16.3)17 (11.6)21 (16.3)  Osteoarthritis^e^12 (8.2)6 (4.7)19 (13.0)19 (14.7)  Cancer04 (3.1)6 (4.1)7 (5.4)  Hyperostosis^f^1 (0.7)02 (1.4)0  Hypocalcemia01 (0.8)01 (0.8)  Osteonecrosis of the jaw^c^001 (0.7)0  Atypical femoral fracture^c^001 (0.7)0^a^Incidence rates were cumulative and included all events in the double-blind and open-label period (to 27 February 2017) in patients who received ≥ 1 dose of open-label alendronate; ^b^events that occurred in ≥ 10% of patients in either group during the double-blind period; ^c^serious cardiovascular adverse events were adjudicated by the Duke Clinical Research Institute, and potential cases of osteonecrosis of the jaw and atypical femoral fracture were adjudicated by independent committees; ^d^identified by prespecified MedDRA search strategies; ^e^prespecified events reported under the osteoarthritis search strategy were osteoarthritis, spinal osteoarthritis, and arthritis; ^f^prespecified events reported under the hyperostosis search strategy were spinal column stenosis and vertebral foraminal stenosis

Among East Asian patients, two adjudicated serious cardiovascular AEs were observed in each treatment group during the double-blind period (cardiac ischemic events, *n* = 1 in each group; cerebrovascular events, *n* = 1 romosozumab group; heart failure, *n* = 1 alendronate group; Table [2](#Tab2){ref-type="table"}).

No adjudicated events of osteonecrosis of the jaw or atypical femoral fracture were reported in the romosozumab treatment arm throughout the double-blind period, while one of each event was positively adjudicated during the open-label period in the alendronate-only group.

Throughout the trial, binding anti-romosozumab antibodies were observed in 12.4% (16/129) of East Asian patients who received romosozumab, and the development of neutralizing antibodies occurred infrequently (0.8% \[1/129\]). Consistent with findings from the global ARCH analysis, there was no evidence that anti-romosozumab antibodies had an impact on the efficacy or safety of romosozumab among East Asian patients.

Rates of AEs were generally similar across the romosozumab and alendronate groups (Table [2](#Tab2){ref-type="table"}), similar to rates seen in the global population \[[@CR27]\], and consistent with the known safety profile of romosozumab.

Discussion {#Sec13}
==========

In this post hoc analysis of ARCH, East Asian postmenopausal women with severe osteoporosis and at high fracture risk who were treated with romosozumab for 12 months before receiving alendronate experienced greater reductions in fracture risk and significantly increased BMD at all sites compared with those who received just alendronate, a current standard of care for osteoporosis treatment. These findings are consistent with those observed in the overall ARCH population, which confirmed that the efficacy of romosozumab is superior to that of alendronate in postmenopausal women with osteoporosis at high risk of fracture \[[@CR27]\].

Even though this subanalysis was not powered to determine treatment effects between subgroups, its findings are important, timely, and clinically relevant for Asia. Alendronate, the most widely used anti-osteoporosis agent in Asia \[[@CR14]--[@CR16]\], is an efficacious drug that was outperformed by romosozumab in a well-designed, global, phase III study \[[@CR27]\]. ARCH is one of the first registrational studies of a bone-building agent vs an antiresorptive therapy designed with fracture prevention as the primary endpoint \[[@CR27]\]. Compared with the placebo-controlled FRAME study, ARCH enrolled patients with more severe osteoporosis or higher fracture risk at baseline, a population with a current unmet medical need that requires rapid and potent antifracture efficacy. The East Asian subpopulation enrolled in ARCH closely reflects patients seen in real-life clinical practice in Asia.

As with the global ARCH population, reduced fracture risk among East Asian patients was observed in the first year of therapy, highlighting the ability of romosozumab to offer potent and rapid fracture prevention, as well as BMD gain benefits, which are key aspects important for practice. These findings may be especially important in Asia, where osteoporosis remains largely underdiagnosed and undertreated, and where the burden of imminent risk of fracture continues to increase \[[@CR8], [@CR9], [@CR29]\]. Patients in Asia may have their osteoporosis identified later in the disease course, creating a need for a therapy that offers potent and rapid antifracture benefit to high-risk patients. In addition, clinical decisions are not regularly informed by bone-density assessments as access to DXA scans is limited in the region. As such, antifracture efficacy of osteoporosis treatments, as informed by fracture risk reduction, is especially helpful in the decision-making process for clinicians in Asia.

Romosozumab therapy was well tolerated in East Asian patients, and the safety profile was generally consistent with that for the global population of patients with postmenopausal osteoporosis. Rates of injection-site reaction and hypersensitivity, which are known adverse reactions with romosozumab, were higher in East Asian patients in both treatment arms compared with the global population and appear to have been driven by the smaller sample size in the East Asian population; however, rates of treatment discontinuation were similar to those of the overall population, suggesting that AEs were manageable. While an imbalance in positively adjudicated serious cardiovascular AEs was observed in the overall ARCH population (50 vs 38 cases at 12 months), the incidence rates in the East Asian subgroup were balanced, occurring in only two patients per treatment arm at 12 months, although the sample size may be too small to draw meaningful conclusions.

A limitation of the current post hoc analysis is that ARCH was not powered to detect differences in treatment effect in the East Asia subgroup. The heterogeneity of ethnicities across East Asia also precludes generalizing these results for the rest of Asia.

Nevertheless, findings from this subanalysis add to previous published findings of romosozumab clinical studies in the Asia Pacific region. Prior studies have shown that romosozumab provides similar pharmacokinetic attributes between healthy global and Japanese postmenopausal populations (study 20090378), as well as similar dose--response profiles between global and East Asian postmenopausal populations in phase II (20060326 and Ishibashi et al., 2017 \[[@CR30]\]) and phase III studies (20070337). In postmenopausal Japanese women with osteoporosis, romosozumab treatment has been shown to lead to large and significant BMD gains \[[@CR30]\] and substantial reductions in fracture risk \[[@CR31]\] compared with placebo. Taken together, these studies suggest no clinically significant interethnic difference in the effects of romosozumab between the global population and patients in East Asia for the treatment of osteoporosis in postmenopausal women at high fracture risk.

Conclusions {#Sec14}
===========

Among East Asian patients, rapid BMD gains from bone-forming therapy with romosozumab followed by alendronate were associated with a lower risk of new vertebral, clinical, non-vertebral, and hip fractures than with alendronate alone over the course of 2 years of treatment. Romosozumab treatment was well tolerated in East Asian patients; AEs were generally similar to those observed in the global population and consistent with the known safety profile of romosozumab. The imbalance in positively adjudicated serious cardiovascular AEs seen in the overall ARCH population was not observed in the East Asian subgroup, although the sample size may be too small to draw meaningful conclusions. The impressive fracture risk reductions observed with romosozumab treatment in both the global and East Asian populations confirm the benefits of initiating treatment with an anabolic agent followed by an antiresorptive compared with starting with antiremodeling therapy, especially in patients at high or imminent risk of fracture.
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